Westmead Hospital

Hospital


Location: Westmead, Australia (AU) AU

ISNI: 0000000101806477

ROR: https://ror.org/04gp5yv64

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients (2023) Rouet R, Henry JY, Johansen MD, Sobti M, Balachandran H, Langley DB, Walker GJ, et al. Journal article Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis (2023) May T, Bernardini M, Lheureux S, Aben KK, Bandera EV, Beckmann M, Benitez J, et al. Journal article p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study (2023) Köbel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, et al. Journal article, Original article Endoscopic submucosal dissection techniques and technology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review (2023) Libanio D, Pimentel-Nunes P, Bastiaansen B, Bisschops R, Bourke MJJ, Deprez PHH, Esposito G, et al. Journal article, Review article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article Pathology Reporting of Gastric Endoscopic Resections: Recommendations From the International Collaboration on Cancer Reporting (2023) Shi C, Webster F, Nagtegaal ID, Bourke MJ, Hong Sm, Kumarasinghe MP, Lam AK, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022 (2022) Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, et al. Journal article KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution
1 2 3